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inverse-electron-demand Diels–Alder reactions.
Potential applications for pretargeted in vivo PET
imaging†
Emilie M. F. Billaud,a Elnaz Shahbazali,b Muneer Ahamed,a Frederik Cleeren,a
Timothy Noe¨l,b Michel Koole,c Alfons Verbruggen,a Volker Hesselb
and Guy Bormans*a
Pretargeted PET imaging has emerged as an eﬀective two-step in vivo approach that combines the superior
aﬃnity and selectivity of antibodies with the rapid pharmacokinetics and favorable dosimetry of smaller
molecules radiolabeled with short-lived radionuclides. This approach can be based on the bioorthogonal
inverse-electron-demand Diels–Alder (IEDDA) reaction between tetrazines and trans-cyclooctene (TCO)
derivatives. We aimed to develop new [18F]TCO–dienophiles with high reactivity for IEDDA reactions, and
favorable in vivo stability and pharmacokinetics. New dienophiles were synthesized using an innovative
micro-ﬂow photochemistry process, and their reaction kinetics with a tetrazine were determined. In vivo
stability and biodistribution of the most promising 18F-radiolabeled-TCO-derivative ([18F]3) was
investigated, and its potential for in vivo pretargeted PET imaging was assessed in tumor-bearing mice.
We demonstrated that [18F]3 is a suitable dienophile for IEDDA reactions and for pretargeting applications.Introduction
In the eld of cancer research, radiolabeled monoclonal anti-
bodies directed against tumor-associated antigens have emerged
as promising vectors to visualize or treat cancer lesions, due to
their high aﬃnity and specicity.1,2 However, because of their
high molecular weight (150 kDa), antibodies usually have long
biological half-lives, thus requiring multiple days to clear from
blood and non-target tissues, and to reach an optimal accumu-
lation in tumor. Therefore, radionuclides with relatively long
physical half-lives must be employed to radiolabel antibodies for
direct in vivo imaging. For instance, zirconium-89 (t1/2 ¼ 78.4 h)
can be used for positron emission tomography (PET) imaging.3
This however leads to high radiation doses in healthy tissues for
patients.
On the other hand, uorine-18 (t1/2 ¼ 110 min) is the PET
radionuclide of choice given its favorable properties including
its decay mode (97% b+ emission), low positron energy (634 keVof Pharmaceutical and Pharmacological
g, O&N2, Herestraat 49, Box 821, 3000
euven.be
gy, Chemical Engineering and Chemistry
5600 MB Eindhoven, The Netherlands
Department of Imaging and Pathology,
aat 49, Box 7003, 3000 Leuven, Belgium
tion (ESI) available. See DOI:
Chemistry 2016maximum), and short b+ trajectory in tissues (<2.3 mm). Its
half-life is long enough to allow multistep syntheses but is short
enough to avoid extended irradiation of patients. Moreover, it
can be produced in large quantities (>400 GBq per batch) with
a cyclotron.4
Combination of antibodies with uorine-18 is challenging,
due to the incompatibility between the long plasma half-life of
the antibody and the short physical half-life of the radionuclide.
Pretargeting addresses this issue in two steps.5 First, a non-
radiolabeled antibody modied with a tag is administered. Few
days later, when the antibody has reached a maximum uptake
in the tumor and a suﬃcient clearance from non-target tissues,
a relatively small radiolabeled molecule is injected. The latter
has the property to selectively bind to the antibody via the tag,
while the non-bound radiotracer is rapidly cleared. Then, high
contrast images can be acquired few hours aer the injection of
the radiolabeled molecule. The overall radiation dose for
patients is thus reduced, compared to the use of an antibody
directly labeled with 89Zr for instance.
Pretargeting approaches can be based on an inverse-elec-
tron-demand Diels–Alder (IEDDA) click reaction between
1,2,4,5-tetrazines and trans-cyclooctene (TCO) derivatives.6
Indeed, this fast, selective, high-yield, biocompatible, and bio-
orthogonal reaction has already proven to be suitable for this kind
of applications, both in vitro and in vivo,7 even using 18F-labeled
tetrazines.8 However, to the best of our knowledge, no in vivo
pretargeting PET imaging results have been reported on usingChem. Sci.
Fig. 1 Chemical structures of previously reported TCO derivative 19
and newly developed dienophiles 2a, 2b, and 3.
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View Article Onlinea 18F-labeled small TCO compound, although this approach may
have specic advantages with regard to pharmacokinetics and
stability. Some radiolabeling procedures were developed for TCO
[18F]1 (Fig. 1)9 but it was applied as a prosthetic group for subse-
quent 18F-labeling of biologically-active molecules.10
Wyﬀels et al. explored biodistribution of [18F]1 in healthy
mice, from 5 to 240 min p.i.9b Results demonstrated renal and
hepatobiliary clearance of radioactivity, slow blood clearance, as
well as increasing bone uptake values (from 60 min p.i.). The
bone uptake is due to deuorination, as [18F]F is known to
have a high aﬃnity for bone, and is an indication of tracer
instability. Therefore, we aimed to develop new TCO derivatives,
with improved in vivo stability, favorable pharmacokinetics, and
high reactivity for IEDDA reactions.
We designed compounds 2a, 2b and 3 derivatised with poly-
ethylene glycol (PEG) chains (Fig. 1) with the aim to increase their
hydrophilicity and their stability towards enzymatic degrada-
tion.7l,11 We developed a conformationally-strained dioxolane-
fused trans-cyclooctene (3), encouraged by the results reported by
Darko et al.12 Indeed, it was demonstrated that this strained
trans-cyclooctenes react faster with 3,6-diphenyl-s-tetrazine than
non strained analogs, and display excellent chemical stability
in aqueous solutions and plasma. Moreover, dioxolane-fused
trans-cyclooctenes can be prepared easily through diaster-
eoselective synthesis.
Herein we report (i) the syntheses of new TCO derivatives, via
a trans-for-cis photoisomerization step using an innovative
micro-ow process; (ii) reaction kinetics of these new dien-
ophiles with a tetrazine, as well as their stability in aqueous
solution; (iii) 18F-radiolabeling of the most promising TCO
derivative 3; (iv) in vitro stability of [18F]3 and in vivo bio-
distribution studies aer injection of [18F]3; (v) proof of prin-
ciple in vitro and in vivo pretargeting experiments using [18F]3.Results and discussion
Syntheses
New dienophiles 2a, 2b and 3 were prepared as shown in
Scheme 1. First, the corresponding cis-derivatives 9 and 18 were
synthesized, in 6 and 7 steps respectively.Chem. Sci.PEG synthon 4 was obtained in two steps starting from
tetraethylene glycol: protection of one hydroxyl group using
triisopropylsilyl (TIPS) chloride followed by mesylation of the
other hydroxyl group. Then, synthon 4 was used for nucleo-
philic substitution with cis-cyclooctenol to yield derivative 5.
The choice of TIPS as the hydroxyl protecting group was
important to obtain a good yield. Aer deprotection using
tetrabutylammonium uoride (TBAF), the hydroxyl group of
compound 6 was replaced by uorine (9) via a sulfonate
intermediate.
For the synthesis of 18, PEG synthon 13 was rst prepared in
two steps starting from tetraethylene glycol: aer protection of
one hydroxyl group using benzoyl chloride (BzCl), the other
hydroxyl was oxidized to an aldehyde in the presence of
Dess–Martin periodinane reagent. In parallel, oxidation of
1,5-cyclooctadiene into diol 12 was carried out using cetyl-
trimethylammonium permanganate. Then, PEG synthon 13
and diol 12 were involved in an acetalization, leading to diox-
olane 14. The stereochemistry of 14 was determined according
to Darko et al.12 Aer deprotection using LiOH, the hydroxyl
group of compound 15 was replaced by uorine (18) via
a sulfonate intermediate.
Trans-for-cis isomerization of hydroxy-derivatives 6, 15,
sulfonate precursors for radiouorination 7, 8, 16, 17, and u-
oro-derivatives 9, 18 was performed using an innovative micro-
ow photochemistry process. Basic design of the setup was
based on the work of Royzen et al.13 This group devised an
apparatus where the reaction mixture, containing a cis-cyclo-
octene derivative and methyl benzoate (a singlet sensitizer),
is photoirradiated at 254 nm, and continuously circulated
through a bed of AgNO3-impregnated silica gel. The trans-
cyclooctene derivative forms a complex with Ag+ and is selec-
tively retained on the bed, while the corresponding cis-cyclo-
octene binds weakly to Ag+ and elutes back to the reaction ask,
where it is photoirradiated again. For trans-for-cis isomerization
of our compounds, we used a micro-ow setup, since the short
characteristic inner diameter of the microreactor allows a high
overall absorption even at larger concentration which increases
the gross conversion rate largely and reduces the reaction time
from hours to minutes for typical photo-ow processes.14 In
addition, process scale-up is facilitated by the numbering-up of
several ow microcapillaries with almost identical perfor-
mance.15 Two microreactors coiled around the UV lamp were
used in parallel, and ow was adjusted to result in 2 to 3 min
irradiation time (Scheme 2 and ESI†). Although Royzen et al.
used 8 lamps of 35 W (light intensity: 12 800 mW cm2),13
a single UV lamp of 10 W (light intensity: 21–24 mW cm2)
provided suﬃcient power for the isomerization reaction in our
micro-ow setup. In-ow separation process based on Ag+
complexation was also optimized, by using several packed beds
made of AgNO3-impregnated silica gel and glass beads. During
experiment, ow was switched aer 30–90min from one packed
bed to the next, in order to avoid saturation. Aer experiment,
a NH4OH solution was used to liberate the trans-compound.
With this optimized method using microreactors, 85% conver-
sion can be achieved for trans-for-cis isomerization of cyclo-
octenol in 3 h (ESI†), compared to a reported 73% in 8 h or 70%This journal is © The Royal Society of Chemistry 2016
Scheme 1 Syntheses of dienophiles 2a, 2b and 3.
Scheme 2 Microﬂuidic setup optimized for trans-for-cis isomeriza-
tion of functionalized cyclooctene derivatives.
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View Article Onlinein 3 h for non-microuidic productions.13,16 For the new func-
tionalized cyclooctene derivatives, photoisomerization yields
reached 76% for a 6 h experiment, with uoro-compound 3. ForThis journal is © The Royal Society of Chemistry 2016sulfonate precursors, only mesylate 11b and 20 could be isolated
aer isomerization, but 11b was quite unstable (data not shown).
Reactivity and stability of new dienophiles
Rate constants for reaction between new dienophiles and
3,6-di(pyridin-2-yl)-1,2,4,5-tetrazine in MeOH at 25 C were
determined by UV-spectrophotometry at 290 nm under pseudo-
rst order conditions (Fig. S2†). Compounds 10a and 10b react
with the tetrazine with rate constants of 476  33 M1 s1 and
1913 196M1 s1 respectively. Compared to trans-cyclooctenol
rate constants (392  6 M1 s1 for major isomer and 300 
22 M1 s1 for minor isomer), the presence of the PEG chain on
10a and 10b does not reduce the reactivity. Reaction rate of 19
with the tetrazine is also fast, with a rate constant of 1620 
149 M1 s1. These rate constants are comparable to the onesChem. Sci.
Fig. 2 Biodistribution of radioactivity after injection of [18F]3 in healthy NMRI mice in selected organs and ﬂuids. Data are expressed as stan-
dardized uptake value (SUVw).
Scheme 3 Reaction between dienophile [18F]3 and tetrazine 21 leads
to [18F]22 (mixture of isomers) quantitatively in a few seconds.
Chem. Sci.
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View Article Onlinereported in literature for this type of dienophiles.6a,12 While the
new dienophiles are reactive toward a tetrazine, they also display
excellent stability. Indeed, uoro-trans-derivatives 2a, 2b and 3
are stable in phosphate-buﬀered saline (PBS, pH 7.4) at 37 C for
19 h at least, as determined by HPLC (Tables S3, S5 and S7†).Radiolabeling with uorine-18
In view of the limited stability of precursors for radio-
uorination 11a and 11b, we decided to continue the project
with dioxolane-fused trans-cyclooctene compounds only. Semi-
automated radiosynthesis of [18F]3 was performed on a home-
made module. Nucleophilic substitution on mesylate precursor
20 by reaction with dry K[18F]F, K222 complex was achieved in
MeCN at 90 C for 15 min. During radiosynthesis of [18F]3, less
than 1% of cis-compound [18F]18 was generated. Aer puri-
cation by HPLC, [18F]3 was obtained in 60 min, with 12%
radiochemical yield (decay-corrected), a radiochemical purity
>99% (Fig. S4†), and a specic activity of 70–188 GBq mmol1.In vitro stability of [18/19F]3
In PBS (pH 7.4), [18F]3 was rather stable, with 94% of intact
compound aer 2 h incubation at 37 C. In rat plasma, [18F]3
slowly isomerized into the corresponding cis-derivative [18F]18,
with 52% and 34% of intact trans-compound aer 1 h and 2 h
incubation at 37 C respectively (Fig. S5†). For pretargeted PET
imaging, this slow degradation is not an issue, as the IEDDA
reaction takes place in a few seconds and plasma clearance is
expected to be relatively fast (<30 min). Additional experiments
were performed to investigate the cause(s) of the isomer-
ization,7b,12 and the presence of a thiol (2-mercaptoethanol) orThis journal is © The Royal Society of Chemistry 2016
Fig. 3 Percentage of binding of radioactivity to LNCaP tumor slices after a pretargeting experiment with successive addition of 21 and [18F]3 or
after incubation with [18F]22 was signiﬁcantly higher than in control experiments.
Edge Article Chemical Science
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View Article Onlinetemperature were found to promote cis-for-trans isomerization
of 3 (Table S8 and Fig. S3†).Biodistribution of radioactivity aer injection of [18F]3
Pharmacokinetic prole of [18F]3 was evaluated in vivo, in
healthy NMRImice, from 2 to 60min p.i. (Fig. 2 and Table S11†).
Results demonstrate absence of in vivo deuorination, as no
signicant bone uptake was observed at 60 min p.i. (0.3 
0.0 SUVw). Radioactivity was cleared via urinary and hepatobiliary
systems. Interestingly, brain uptake was observed (1.3 0.2 to 0.6
 0.0 SUVw from 2 to 60 min p.i.). Analysis of brain and biouids
by HPLC aer 15 min p.i. revealed 20.8  1.1% of intact [18F]3 in
brain, 5.9  0.6% in plasma and 0.1  0.0% in urine (Fig. S6†),
indicating fast metabolism.In vitro pretargeting experiments using [18F]3
To check the usefulness of [18F]3 as a new dienophile for IEDDA
reactions and for pretargeted PET imaging, in vitro and in vivo
experiments were performed using a pseudo peptide with
aﬃnity for prostate-specic membrane antigen (PSMA)17
conjugated to 3-(4-(triuoromethyl)phenyl)-6-phenyl-1,2,4,5-
tetrazine10f (21, Scheme 3, synthesis described in ESI†).
For in vitro experiments, prostate tumor slices (LNCaP and
PC-3 cells) were incubated with 21, washed, and [18F]3 was
added. Direct incubation with “preclicked”-compound [18F]22This journal is © The Royal Society of Chemistry 2016(Scheme 3, Fig. S7†) was also performed. To check the specicity
of the approach, blocking experiments with the non-structural
related inhibitor 2-(phosphonomethyl)pentane-1,5-dioic acid18
and incubation with [18F]3 only were also carried out. The
fraction of bound activity was determined aer autoradiography
(Fig. 3 and S9†). Signicant PSMA-specic binding to LNCaP
tumor slices (expressing PSMA receptors) was observed in the
pretargeting experiment, but it was lower than the specic
binding of “preclicked”-compound [18F]22. In PC-3 cells (nega-
tive control), no signicant binding was observed.Proof of principle in vivo PET imaging
On the basis of these promising results, proof of principle PET
imaging experiments were conducted in LNCaP prostate tumor-
bearing mice. Compound 21 (50 mg) was administered intra-
tumorally 10 min before intravenous (i.v.) injection of [18F]3,
following a similar protocol reported by Emmetiere et al.,7f to
avoid variability due to tetrazine concentration in target tissues.
Dynamic (0–60min p.i.) and static (120min p.i.) microPET scans
were acquired. PET imaging with [18F]3 allowed visualization of
the tumor, as shown in Fig. 4. Moreover, tumor uptake was
signicantly higher than muscle uptake, as early as 30 min p.i.
and up to 2 h p.i. In order to ensure that the tumor accumulation
was due to the 18F-labeled conjugate formed by the IEDDA
reaction, control experiments were also performed in mice that
received only i.v. injection of [18F]3. Uptake of radioactivity in theChem. Sci.
Fig. 5 (A) In vivo PET images 60 min after i.v. injection of [18F]3 (11 MBq) in an healthy NMRI mouse which received an intramuscular injection of
tetrazine 21 (50 mg) in the muscle on the right shoulder (arrows), and saline with 10% dimethyl sulfoxide in the muscle on the left shoulder. (B)
Time–activity curves from 0 to 60 min after i.v. injection of [18F]3, in healthy NMRI mice (N ¼ 3). The uptake of radioactivity in the tetrazine-
enriched tissue is signiﬁcantly higher than in the tissue which received only the vehicle, from 3 min to 47 min p.i. of [18F]3.
Fig. 4 (A) In vivo PET images 2 h after i.v. injection of bioorthogonal [18F]3 (11 MBq), in a mouse bearing an LNCaP tumor treated with tetrazine 21
(50 mg). (B) Time–activity curves from0 to 60min after i.v. injection of [18F]3, in LNCaP tumor-bearingmicewith (N¼ 3) or without (¼control,N¼
3) intratumoral injection of 21.
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View Article Onlinetumor was signicantly lower than in tetrazine-21-preinjected
tumors, from 30 min to 2 h p.i. (Fig. 4 and S10†). No signicant
diﬀerence was observed between muscle uptake and tumor
uptake in control experiments. According to another PET
imaging experiment (Fig. 5 and S11†), the accumulation of
radioactivity in tetrazine-enriched tissues is not an eﬀect due to
the injection of the tetrazine, as the injection of the same volume
of vehicle alone (saline with 10% dimethyl sulfoxide) does not
lead to a signicant uptake of radioactivity.
These proof of principle experiments demonstrate the
usefulness of [18F]3 for the in vivo IEDDA reaction. In order
to successfully apply this new dienophile to pretargeted
immunoPET, stability will be favored over reactivity for the
choice of the tetrazine, as a tetrazine-derivatised antibody will
be injected several days before the radiolabeled dienophile. A
tetrazine such as reported by Selvaraj et al.,10f or by Karver
et al.,7c possibly modied with a PEG linker, might be a good
choice.Chem. Sci.Conclusions
In summary, we developed three new dienophiles for IEDDA
reactions, and compound 3 was selected for pretargeting
applications. trans-3 has been prepared via diastereoselective
synthesis, and the trans-for-cis isomerization step has been
performed by micro-ow photochemistry with 76% yield. The
new microuidic setup reported here can be applied as
continuous process which is promising for process scale-up.
18F-radiolabeling of 3 can be carried out by nucleophilic
substitution at high specic activity, in 60 min, with 12%
radiochemical yield, and >99% radiochemical purity. In vivo,
[18F]3 demonstrated a suitable pharmacokinetic prole and no
deuorination was observed. Proof of principle PET imaging
experiments with [18F]3, on a prostate tumor model injected
with a tetrazine-coupled PSMA antagonist 10 min before
radiotracer injection, allowed clear visualization of the tumor
tissue, due to the 18F-labeled conjugate formed by the IEDDAThis journal is © The Royal Society of Chemistry 2016
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View Article Onlinereaction. In conclusion, new dienophile [18F]3 seems suitable
for pretargeted PET imaging, although further structural
modication can still be done to favor urinary excretion. In the
future, [18F]3 will be investigated for pretargeted immunoPET,
by using a tetrazine-derivatised antibody.
Acknowledgements
The authors thank Julie Cornelis, Pieter Haspeslagh, Ivan
Sannen, Michiel Nuyts, Jana Hemelaers from the Laboratory of
Radiopharmacy, and Ann Van Santvoort, Tinne Buelens from
Nuclear Medicine and Molecular Imaging, for their assistance.
This research project received support from IWT Flanders (SBO
130065 MIRIAD) and the European Research Council (Advanced
Grant “Novel Process Windows – Boosted Micro Process Tech-
nology” 267443).
References
1 E. D. G. Fleuren, Y. M. H. Versleijen-Jonkers, S. Heskamp,
C. M. L. van Herpen, W. J. G. Oyen, W. T. A. van der Graaf
and O. C. Boerman, Mol. Oncol., 2014, 8, 799.
2 L. E. Lamberts, S. P. Williams, A. G. T. Terwisscha van
Scheltinga, M. N. Lub-de Hooge, C. P. Schro¨der,
J. A. Gietema, A. H. Brouwers and E. G. E. de Vries, J. Clin.
Oncol., 2015, 33, 1491.
3 M. A. Deri, B. M. Zeglis, L. C. Francesconi and J. S. Lewis,
Nucl. Med. Biol., 2013, 40, 3.
4 K. Serdons, A. Verbruggen and G. M. Bormans, Methods,
2009, 48, 104.
5 D. A. Goodwin, C. F. Meares, M. J. McCall, M. McTigue and
W. Chaovapong, J. Nucl. Med., 1988, 29, 226.
6 (a) M. L. Blackman, M. Royzen and J. M. Fox, J. Am. Chem.
Soc., 2008, 130, 13518; (b) T. Reiner and B. M. Zeglis, J.
Labelled Compd. Radiopharm., 2014, 57, 285.
7 (a) N. K. Devaraj, R. Upadhyay, J. B. Haun, S. A. Hilderbrand
and R. Weissleder, Angew. Chem., Int. Ed., 2009, 48, 7013; (b)
R. Rossin, P. Renart Verkerk, S. M. van den Bosch,
R. C. M. Vulders, I. Verel, J. Lub and M. S. Robillard,
Angew. Chem., Int. Ed., 2010, 49, 3375; (c) M. R. Karver,
R. Weissleder and S. A. Hilderbrand, Bioconjugate Chem.,
2011, 22, 2263; (d) G. Budin, H. Jung Chung, H. Lee and
R. Weissleder, Angew. Chem., Int. Ed., 2012, 51, 7752; (e)
R. Rossin, S. M. van den Bosch, W. ten Hoeve, M. Carvelli,
R. M. Versteegen, J. Lub and M. S. Robillard, Bioconjugate
Chem., 2013, 24, 1210; (f) F. Emmetiere, C. Irwin,
N. T. Viola-Villegas, V. Longo, S. M. Cheal, P. Zanzonico,
N. Pillarsetty, W. A. Weber, J. S. Lewis and T. Reiner,
Bioconjugate Chem., 2013, 24, 1784; (g) B. M. Zeglis,
K. K. Sevak, T. Reiner, P. Mohindra, S. D. Carlin,
P. Zanzonico, R. Weissleder and J. S. Lewis, J. Nucl. Med.,
2013, 54, 1389; (h) R. Rossin, T. La¨ppchen, S. M. van den
Bosch, R. Laforest and M. S. Robillard, J. Nucl. Med., 2013,
54, 1989; (i) H. L. Evans, Q.-D. Nguyen, L. S. Carroll,
M. Kaliszczak, F. J. Twyman, A. C. Spivey and
E. O. Aboagye, Chem. Commun., 2014, 50, 9557; (j)
R. Rossin, S. M. J. van Duijnhoven, T. La¨ppchen, S. M. vanThis journal is © The Royal Society of Chemistry 2016den Bosch and M. S. Robillard, Mol. Pharmaceutics, 2014,
11, 3090; (k) S. M. J. van Duijnhoven, R. Rossin, S. M. van
den Bosch, M. P. Wheatcro, P. J. Hudson and
M. S. Robillard, J. Nucl. Med., 2015, 56, 1422; (l)
B. M. Zeglis, C. Brand, D. Abdel-Atti, K. E. Carnazza,
B. E. Cook, S. Carlin, T. Reiner and J. S. Lewis, Mol.
Pharmaceutics, 2015, 12, 3575; (m) J. L. Houghton,
B. M. Zeglis, D. Abdel-Atti, R. Sawada, W. W. Scholz and
J. S. Lewis, J. Nucl. Med., 2016, 57, 453; (n) M. Altai,
A. Perols, M. Tsourma, B. Mitran, H. Honarvar,
M. Robillard, R. Rossin, W. ten Hoeve, M. Lubberink,
A. Orlova, A. Eriksson Karlstro¨m and V. Tolmachev, J. Nucl.
Med., 2016, 57, 431; (o) N. K. Devaraj, R. Weissleder and
S. A. Hilderbrand, Bioconjugate Chem., 2008, 19, 2297; (p)
B. Nichols, Z. Qin, J. Yang, D. R. Vera and N. K. Devaraj,
Chem. Commun., 2014, 50, 5215.
8 (a) N. K. Devaraj, G. M. Thurber, E. J. Keliher, B. Marinelli
and R. Weissleder, Proc. Natl. Acad. Sci. U. S. A., 2012, 109,
4762; (b) C. Denk, D. Svatunek, T. Filip, T. Wanek,
D. Lumpi, J. Fro¨hlich, C. Kuntner and H. Mikula, Angew.
Chem., Int. Ed., 2014, 53, 9655; (c) J.-P. Meyer,
J. L. Houghton, P. Kozlowski, D. Abdel-Atti, T. Reiner,
N. V. K. Pillarsetty, W. W. Scholz, B. M. Zeglis and
J. S. Lewis, Bioconjugate Chem., 2016, 27, 298.
9 (a) Z. Li, H. Cai, M. Hassink, M. L. Blackman, R. C. D. Brown,
P. S. Conti and J. M. Fox, Chem. Commun., 2010, 46, 8043; (b)
L. Wyﬀels, D. Thomae, A.-M. Waldron, J. Fissers,
S. Dedeurwaerdere, P. Van der Veken, J. Joossens,
S. Stroobants, K. Augustyns and S. Staelens, Nucl. Med.
Biol., 2014, 41, 513.
10 (a) T. Reiner, E. J. Keliher, S. Earley, B. Marinelli and
R. Weissleder, Angew. Chem., Int. Ed., 2011, 50, 1922; (b)
R. Selvaraj, S. Liu, M. Hassink, C.-W. Huang, L.-P. Yap,
R. Park, J. M. Fox, Z. Li and P. S. Conti, Bioorg. Med. Chem.
Lett., 2011, 21, 5011; (c) E. J. Keliher, T. Reiner,
G. M. Thurber, R. Upadhyay and R. Weissleder,
ChemistryOpen, 2012, 1, 177; (d) Z. Wu, S. Liu, M. Hassink,
I. Nair, R. Park, L. Li, I. Todorov, J. M. Fox, Z. Li,
J. E. Shively, P. S. Conti and F. Kandeel, J. Nucl. Med., 2013,
54, 244; (e) S. Liua, M. Hassink, R. Selvaraj, L.-P. Yap,
R. Park, H. Wang, X. Chen, J. M. Fox, Z. Li and P. S. Conti,
Mol. Imaging, 2013, 12, 121; (f) R. Selvaraj, B. Giglio, S. Liu,
H. Wang, M. Wang, H. Yuan, S. R. Chintala, L.-P. Yap,
P. S. Conti, J. M. Fox and Z. Li, Bioconjugate Chem., 2015,
26, 435.
11 (a) G. Molineux, Cancer Treat. Rev., 2002, 28(A), 13; (b)
J. M. Harris and R. B. Chess, Nat. Rev. Drug Discovery,
2003, 2, 214; (c) F. M. Veronese and G. Pasut, Drug
Discovery Today, 2005, 10, 1451.
12 A. Darko, S. Wallace, O. Dmitrenko, M. M. Machovinac,
R. A. Mehl, J. W. Chin and J. M. Fox, Chem. Sci., 2014, 5, 3770.
13 M. Royzen, G. P. A. Yap and J. M. Fox, J. Am. Chem. Soc., 2008,
130, 3760.
14 (a) D. Cambie, C. Bottecchia, N. J. W. Straathof, V. Hessel
and T. Noe¨l, Chem. Rev., 2016, 116, 10276; (b) Y. Su,
N. J. W. Straathof, V. Hessel and T. Noe¨l, Chem.–Eur. J.,
2014, 20, 10562.Chem. Sci.
Chemical Science Edge Article
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
7 
O
ct
ob
er
 2
01
6.
 D
ow
nl
oa
de
d 
on
 1
2/
10
/2
01
6 
18
:4
6:
21
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online15 Y. Su, K. Kuijpers, V. Hessel and T. Noe¨l, React. Chem. Eng.,
2016, 1, 73.
16 D. Svatunek, C. Denk, V. Rosecker, B. Sohr, C. Hametner,
G. Allmaier, J. Fro¨hlich and H. Mikula, Monatsh. Chem.,
2016, 147, 579.Chem. Sci.17 M. Eder, M. Scha¨fer, U. Bauder-Wu¨st, W.-E. Hull,
C. Wa¨ngler, W. Mier, U. Haberkorn and M. Eisenhut,
Bioconjugate Chem., 2012, 23, 688.
18 P. F. Jackson, D. C. Cole, B. S. Slusher, S. L. Stetz, L. E. Ross,
B. A. Donzanti and D. A. Trainor, J. Med. Chem., 1996, 39,
619.This journal is © The Royal Society of Chemistry 2016
